Safety news
News
Articles, announcements and LinkedIn posts from Safety Strategy, newest first.
On 20 October 2026 the MHRA confirmed that the UK marketing authorisation for IXCHIQ, a live attenuated chikungunya vaccine, has been withdrawn. The decision did not rest on a brand-new signal: restrictions by age and comorbidity had not contained the risk, while the benefit for short-term travellers stayed modest. A case study in context-dependent benefit-risk.
Read article: IXCHIQ in the UK: from restriction to revocationSafety Strategy, an independent, physician-led pharmacovigilance practice, launched its website. It covers support with product safety strategy and interim Head of Drug Safety cover, signal management and benefit-risk assessment, EU RMPs, US REMS and additional risk minimisation measures, PSUR/PBRER and DSUR strategy, and PSMF maintenance and GVP inspection readiness, plus a section for PV education materials.
Read on LinkedIn (opens in a new tab)For new posts as they are published, follow Safety Strategy on LinkedIn (opens in a new tab).